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ABSTRACT
Background: Clinical trials remain vital in order to: A) develop new treatment interventions,
and also, B) to guide optimal use of current interventions for the treatment and prevention of
acute and chronic postsurgical pain. Measures of pain (e.g. intensity and relief) and opioid use
have been validated for the settings of postsurgical pain and continue to effectively guide
research in this field..
Methods: This narrative review considers needs for innovation in postsurgical pain trial out-
comes assessment.
Results: Future improvements are needed and include: A) more widespread measurement of
movement-evoked pain with validation of various procedure-relevant movemen-tevoked pain
maneuvers; B) new validated analytical approaches to integrate early postoperative pain scores
with opioid use; and, C) closer attention to the measurement of postoperative opioid use after
hospital discharge. In addition to these traditional measures, consideration is being given to
the use of new pain-relevant outcome domains that include: 1) other symptoms (e.g. nausea
and vomiting), 2) recovery of physiological function (e.g. respiratory, gastrointestinal, genitour-
inary and musculoskeletal), 3) emotional function (e.g. depression, anxiety) and, 4) develop-
ment of chronic postsurgical pain. Also, there is a need to develop pain-related domains and
measures for evaluating both acute and chronic post-operative pain. Finally, evidence suggests
that further needs for improvements in safety assessment and reporting in postsurgical pain
trials is needed, e.g. by using an agreed upon, standardized collection of outcomes that will be
reported as a minimum in all postsurgical pain trials.
Conclusions: These proposed advances in outcome measurement methodology are expected
to improve the success by which postsurgical pain trials guide improvements in clinical care
and patient outcomes.
RÉSUMÉ
Contexte: Les essais cliniques demeurent essentiels pour a) développer de nouvelles interventions
de traitement et b) guider l’utilisation optimale des interventions actuelles pour le traitement et la
prévention de la douleur postopératoire aigue et chronique. Les mesures de la douleur (ex.: intensité
et soulagement) et de l’usage d’opioïdes ont été validées pour les contextes de la douleur
postopératoire et continuent de guider la recherche dans le domaine.
Méthodes: Cet examen narratif porte sur la nécessité d’innover en ce qui concerne les résultats
des études sur l’évaluation de la douleur postopératoire.
Résultats: Des améliorations sont nécessaires, parmi lesquelles on compte: a) une plus grande
généralisation de la mesure de la douleur évoquée par le mouvement avec validation de
diverses manœuvres relatives à la douleur évoquée par le mouvement pertinentes aux inter-
ventions; b) de nouvelles approches analytiques validées afin d’intégrer les scores obtenus
pour la douleur postopératoire précoce et l’usage d’opioïdes; c) une attention plus soutenue à
la mesure de l’usage postopératoire d’opioïdes après le congé de l’hôpital. En plus de ces
mesures traditionnelles, l’utilisation de nouveaux domaines de résultats pertinents à la douleur
sont aussi envisagés, dont : 1) d’autres symptômes (ex. : nausée et vomissements), 2) le
rétablissement de la fonction physiologique (ex. : respiratoire, gastro-intestinale, génito-
urinaire et musculo-squelettique, 3) la fonction émotionnelle (ex. : dépression anxiété) et 4)
le développement de douleur postopératoire chronique. De plus, des domaines et mesures de
la douleur sont nécessaires pour évaluer la douleur aigue et la douleur postopératoire chron-
ique. Finalement, les données probantes suggèrent que des améliorations sont nécessaires
dans l’évaluation de la sécurité, en utilisant par exemple un ensemble minimal de résultats
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convenus et standardisés qui seront utilisésdans toutes les études portant sur la douleur
postopératoire.
Conclusions: On s’attend à ce que les améliorations proposées dans la méthodologie de
mesure des résultats permettent aux études sur la douleur de guider les améliorations en
matière de soins cliniques et de résultats des patients de manière plus fructueuse.
Introduction
Over 300 million surgical procedures are done in the
world each year1 and approximately 60–70% of these are
associated with moderate or severe postsurgical pain.2–4
The clinical goals for acute postsurgical painmanagement
include the relief of pain-related suffering, and the reduc-
tion of pain-related physiological impairment (e.g. immo-
bility, impaired cardio-respiratory, gastrointestinal and
cognitive function, disturbed sleep) in order to accelerate
functional recovery after surgery.5,6 In addition to redu-
cing the severity and adverse effects of postsurgical pain in
the days to weeks after surgery, development of chronic
postsurgical pain that persists beyond 3 months after
surgery has been increasingly recognized as a serious
complication that requires greater attention by surgeons,
anesthesiologists and other perioperative healthcare pro-
viders and researchers.7–10
The evolution of clinical trials of postsurgical pain
treatment and prevention has demonstrated
a dichotomy between: 1) trial designs that facilitate
development of novel analgesic agents, for example by
the pharmaceutical industry, and, 2) more pragmati-
cally oriented trials focused on guiding improvements
in postsurgical clinical outcomes.11 Proof-of-concept
study designs in trials evaluating novel therapies for
postsurgical pain – typically in comparison with inert
placebo – generally emphasize trial feasibility, single-
dose trial designs, high assay sensitivity (i.e. ability of
the trial to demonstrate a treatment versus placebo
difference if one exists) and internal validity.12–14 In
such trials – that typically evaluate novel analgesics
that have shown efficacy in reducing nociception in
preclinical animal models – primary outcome measure-
ment is usually focused on pain intensity or relief.14
Pragmatically oriented study designs of trials focused
on optimizing clinical outcomes – often involving cur-
rently available pain treatments – generally emphasize
generalizability, clinical relevance and importance, and
often involve multi-dose trial designs.11,15 In such trials,
that typically involve various domains of clinical assess-
ment, outcome measures in addition to pain should
whenever possible be included, addressing domains
such as physiological function, patient satisfaction and
time to hospital discharge readiness.11 This article dis-
cusses the current status and future directions of
outcome measures for post-surgical pain trials with
a distinction between trials of acute postsurgical pain
treatment and chronic postsurgical pain prevention.
Traditional Pain-Related Outcome Measures in
Postsurgical Pain Trials
Pain Intensity and Pain Relief
Given their focus, clinical trials of postsurgical pain
almost always include outcome measures of pain inten-
sity or relief, and most often, one of these measures is
defined as the primary outcome of the trial.16 In
a review of 3 meta-analyses of 154, mostly single-dose,
trials of aspirin, acetaminophen and ibuprofen, the
most commonly used outcomes were pain intensity,
pain relief, global improvement measures, rescue
analgesic use, and adverse effects.17 Of note, the major-
ity of these RCTs reported trial treatment group
averages rather than proportions of responders with
a predefined level of treatment response (e.g. 50%
pain reduction). This has been recognized to be proble-
matic because very few patients “behave like the aver-
age” and a more clinically relevant treatment group
measure is the proportion of patients who responded
(e.g. received a 50% pain reduction) to the treatment.18
Historically, various different rating methods have been
used to assess postoperative pain intensity and
relief.14,19,20 Commonly used rating scales include ver-
bal/category scales (e.g. none, mild, moderate or severe
for intensity; none, slight, moderate or complete for
relief), numerical rating scales (e.g. 0–10 scale) or visual
analog scale (e.g. 0–100 mm scale).21,22
Research interest in treatment and prevention of
chronic postsurgical pain has been growing7,23 given
its major negative impact on long-term quality of
life.24,25 Because chronic postsurgical pain is generally
defined as new pain that develops after a surgical pro-
cedure (or, in some situations, increased pain intensity
after the surgical procedure if a patient presented pain
in the operated area before surgery) and persists at least
3 months after surgery,7,26,27 some measure of pain at,
and/or beyond, 3 months after surgery is typically
involved in studies of persistent post-surgical pain.
For example, in a meta-analysis of clinical trials of
drugs studied for the prevention of chronic pain after
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surgery, the most commonly used outcomes were any
(i.e. ≥ zero intensity) pain reported ≥ 3 months after
surgery, and, when persistent pain intensity was actu-
ally rated, ≥ moderate pain ≥ 3 months after surgery.28
It should be noted, however, that more specific defini-
tions and assessment methods of outcome measures
may have an important impact on study results, e.g.
a single telephone pain intensity rating versus a more
robust multiple-day pain diary and also multiple time
points beyond 3 months.
Rescue Opioid Consumption
Over half a century ago, pioneering investigations by
Henry Beecher and others actually used postoperative
opioid consumption as a measure of pain severity after
different surgical procedures – at a time when very few,
if any, non-opioid analgesics were available.29 With the
subsequent investigation into postoperative analgesic
efficacy of non-steroidal anti-inflammatory drugs, the
use of opioids for analgesic rescue stimulated the need
for new analytical approaches to censor and/or impute
pain scores for patients after receiving rescue analgesia
in a trial.14,18,30 The development of patient-controlled
analgesia (PCA) systems with data capture31,32 pro-
vided the ability to assess apparent analgesic responses
to other analgesic treatments, as indicated by
a reduction in PCA opioid consumption.33 Thus, the
concept of opioid sparing as an effect of an investiga-
tional analgesic led to opioid consumption as an impor-
tant outcome measure in postsurgical pain trials
involving rescue analgesic with non-study opioids.11,34
Future Considerations for Other Outcome
Measures
Needs for Improvement in Postsurgical Pain Trials
Movement-evoked pain as a critically important out-
come measure
For several decades, patients, clinicians and research-
ers alike have recognized the important distinction
between pain at rest (PAR) and pain evoked or aggra-
vated by movement (MEP – movement-evoked pain)
such that MEP is generally more severe than PAR.35–37
Previous studies have suggested an association between
MEP and impaired recovery of postoperative physiolo-
gical function38-40 and that analgesic interventions with
effective reduction of MEP result in improved pulmon-
ary outcomes.41,42 Despite this compelling rationale,
a previous systematic review of over 1,800 analgesic
clinical trials involving thoracotomy, hysterectomy and
knee arthroplasty demonstrated that only 39% of trials
actually included MEP as a trial outcome and more than
half of these trials failed to distinguish between PAR and
MEP when defining the trial’s primary outcome.43
Despite prominent recognition of this important
distinction,44 clinical trials continue to fail to distinguish
between PAR and MEP when defining their
outcomes.45,46 Thus, an important future direction for
postsurgical trials is to greatly heighten awareness and
implementation of MEP, in addition to PAR, as
a critically important outcome measure. This must be
done in a procedure-specific set-up with assessment of
procedure-specific, clinically-relevant movement. Ideal
would be the use of agreed upon, reliable and validated
patient-reported outcome measure for MEP based on
a procedure-relevant “movement” but validation of
such measures are needed.
Opioid consumption – an increasingly important
outcome measure
As mentioned above, reduced opioid requirements,
or opioid sparing, after surgery may reflect the analge-
sic efficacy of an investigational pain treatment making
opioid consumption a popular outcome measure in
analgesic trials. However, careful reflection has high-
lighted several limitations of opioid consumption as an
outcome, particularly in the setting of PCA opioid use.
In particular, a weak correlation between pain intensity
and opioid consumption has been observed, which
could be, in part, due to: 1) acute tolerance to opioids,
2) variable training of patients on how to use PCA, 3)
other opioid side effects (e.g. nausea-induced reduc-
tions in PCA use), and, 4) effects of investigational
analgesic on PCA (e.g. sedation-induced reductions in
PCA demand).47 Thus, interpretation of pain scores, as
the sole measure of analgesic treatment response, in
postsurgical placebo-controlled analgesic trials is com-
plicated by PCA opioid use because measured efficacy
differences between placebo and investigational analge-
sic can be partially reduced if greater opioid use, and
opioid-related analgesia, in the placebo group reduces
the placebo versus treatment difference. Also, as dis-
cussed above, reliance on opioid consumption data
alone also has its limitations in making any conclusions
about investigational drug efficacy. For these reasons,
investigators have proposed different analytical
approaches to integrate pain scores and opioid con-
sumption in order to provide a more representative
composite score in postsurgical analgesic trials.48–50
Since uniform agreement has not yet been reached on
an optimal approach, additional research has been
recommended to more confidently conclude whether
such complex analytical approaches provide a more
definitive characterization of the efficacy of an investi-
gational analgesic.14
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The greatest relevance of postoperative opioid con-
sumption as a clinical outcome is related to the well-
recognized adverse effects of opioids affecting neurolo-
gical, respiratory, gastroenterological and genitourinary
systems.51 Thus, regardless of the mechanism, if an
investigational treatment can effectively reduce opioid
use to a degree that will result in reduced opioid-related
adverse effects (without increasing pain), this would
certainly be a clinically important favourable effect.52
In fact, several examples have been described where
multiple trials of interventions with even modest
analgesic efficacy result in significant reductions in
opioid-related adverse effects. For example, postopera-
tive administration of non-steroidal anti-inflammatory
drugs reduced nausea and vomiting,53 and postopera-
tive infusions of intravenous lidocaine accelerated
recovery of postoperative bowel function.54 In fact,
a specific composite scale designed to assess postopera-
tive opioid-related side effects55 has been introduced to
demonstrate the impact of novel analgesic interventions
to reduce opioid-related side effect burden56 and
should be used much more in future trials.
More recently, the largely North American opioid
crisis has focused more attention on the amount of
opioid use before and after surgery.57 Although preo-
perative opioid use and preoperative pain – at or
remote from the surgical site – have been shown to
be associated with a higher risk of persistent postopera-
tive pain,58 some large cohort studies have reported
varying, but concerning, rates of chronic postoperative
opioid use after minor surgery in previously opioid-na
ïve patients.57,59 As this research continues, it has been
recognized that efforts to reduce opioid use, particu-
larly after hospital discharge, requires further
attention60 and, thus, opioid consumption beyond the
early postoperative period is an increasingly important
trial outcome measure.
Do We Need More Outcome Measures?
Recently proposed future research needs for postsurgi-
cal pain management include: 1) development of opti-
mal strategies for the management of pain in
challenging populations (e.g. preexisting chronic pain,
mental health conditions, and substance use disorders);
2) prevention of transition to chronic postsurgical pain;
and, 3) post-hospital discharge management of post-
surgical pain in home/community settings.11 These
newer areas of postsurgical pain research may require
development and implementation of new patient-
centered outcome measures. Such measures will need
to be focused on the population of interest (e.g. out-
comes related to depression, chronic pain, substance
use disorder), or on the surgical procedure of interest
(e.g. measures of functional recovery after total knee
arthroplasty), or on the intervention of interest (e.g.
feasibility outcomes of outpatient indwelling catheters
for regional analgesia).
Relevant to the management of early postoperative
pain, the Standardised Endpoints in Perioperative
Medicine (StEP) initiative used a Delphi approach to
develop and propose 6 defined outcomes for the
domain of “patient comfort” in perioperative medicine
including: 1) pain intensity (at rest and during move-
ment, 24 hours postop), 2) nausea and vomiting, 3)
quality-of-recovery, 4) time to gastrointestinal recovery,
5) time to mobilisation, and 6) sleep quality.61
However, due to a broader perspective, procedure spe-
cific pain-related aspects were not considered and
patient’s perspective was not taken into account.
Future research is needed to elucidate these further in
order to identify (a set of) pain-related outcome
domains and instruments that are best suited for cer-
tain surgical procedures based on evidence. Important
here is a consensus procedure that includes patients, for
example similar to an approach recommended by the
comet initiative (http://www.comet-initiative.org).
Important for measurement instruments to be recom-
mended at the end of clinical trials is feasibility, good
content validity and good internal consistency (http://
www.comet-initiative.org). In addition, future pain
trials should include detailed information on patient-
specific pain risk factors, such as pain catastrophizing,
pre-operative opioid use or other types of “pain-
sensitized” patients.11
The setting of chronic postsurgical pain is perhaps
more complex and involves potential interventions, and
modulating factors, from before the surgical procedure
to the early perioperative period to later time points
after surgery.8,9,27 As such, a broader range of measures
have been proposed for research to better understand
the development of chronic postsurgical pain and its
prevention.62 Such measures are associated with the
domains of patient demographics, pain-related factors,
other clinical diagnoses and comorbidities, surgery-
related factors, psychological/psychiatric factors, physi-
cal functioning, and, global measures of outcome.62
Other domains beyond pain intensity should be con-
sidered for exploring effectiveness of preventive inter-
vention and/or treatment of chronic postoperative pain.
Ideal would be the use of agreed upon pain-related
outcome domains that are similar to those considered
for chronic pain in general,63 but tailored more speci-
fically to chronic postsurgical pain and tied to a core set
of validated instruments.64,65 Such an approach would
enable the identification of clinically relevant effects of
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a treatment, direct comparison of the effect of inter-
ventions between different trials and aligned evidence-
based recommendations.
Safety Outcomes in Postsurgical Pain Trials
Recognition of the importance of appropriately asses-
sing and reporting safety outcomes in clinical trials has
led to publication of the 2004 extension to the
CONSORT statement (Consolidated Standards of
Reporting Trials) using a structured checklist approach
for submission of clinical trial manuscripts.66 Despite
the publication of this statement, recent reports have
suggested that clinical trials published from 2000 to
2011 in the European Journal of Pain, Journal of Pain
and Pain failed to meet 4 of the 10 recommendations of
the 2004 CONSORT harms extension67 and that 40% of
such publications failed to report any information
regarding serious adverse events.68 This area of defi-
ciency has been well recognized in the setting of post-
surgical pain trials dating back to the late 1990s.69
However, despite the 2004 CONSORT harms extension
and the recent reviews suggesting deficiencies in pain
trials in general, more recent evidence suggests that
safety assessment and reporting in postsurgical pain
trials continues to lag behind.70,71 Thus, further atten-
tion to improving the assessment and reporting of
safety outcomes in postsurgical pain trial requires
a concerted, collaborative commitment among research
investigators, ethics review boards, research funding
agencies and journal editorial boards.
Conclusion
Outcome measures of pain (intensity and relief) remain
clinically important and are commonly used in post-
surgical pain trials. Given that opioids remain com-
monly used as rescue medications in trials of early
postsurgical pain, measures of opioid consumption
continue to be necessary and further research is needed
to validate analytical approaches that integrate opioid
consumption and pain in efforts to better estimate
analgesic efficacy of an investigational treatment.
Future initiatives and projects should, however, focus
on identifying a consented set of pain-related outcome
measures that are clinically relevant (including rele-
vance to patients), evidence-based, sensitive to changes,
and validated for its specific use in postoperative
patients.72,73 A consensus on such a core set of patient-
centered outcome measures may be of great value in
novel trials involving specific surgical procedures,
patient populations and unique analgesic interventions.
Finally, assessment and reporting of safety outcomes is
critical in postoperative analgesic trials and requires
further improvement.
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